Home > Journals > Minerva Psichiatrica > Past Issues > Minerva Psichiatrica 1999 March;40(1) > Minerva Psichiatrica 1999 March;40(1):41-6

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

REVIEWS   

Minerva Psichiatrica 1999 March;40(1):41-6

Copyright © 1999 EDIZIONI MINERVA MEDICA

language: Italian

Review on nicotinamide administration in psychiatry

Mastrobuono M.


PDF


Therapies with nicotinic acid and nicotinamide have been advocated as primary or adjuvant therapies in schizophrenia for many years. In depressive syndrome the research with nicotinic acid and nicotinamide has not been broad.
In schizophrenic disease these drugs (nicotinic acid and nicotinamide) act in the body as obligate methyl acceptors and thus may reduce the availability of methyl groups for the formation of schizogenic substances. In depressive syndrome, the mechanism of action of nicotinamide is also known. In our research, therapeutic effect of neuroleptics and paroxetine (SSRI) is augmented by nicotinamide in 40-50% of the cases.

top of page